Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy
To measure the prevalence of JCV-specific antibodies in a French cohort of MS patients treated with natalizumab and to identify risk factor(s) of JCV seropositivity. Progressive multifocal leukoencephalopathy (PML) risk may be stratified by anti-JCV antibody status, duration of natalizumab therapy (...
Gespeichert in:
| Veröffentlicht in: | Journal of neurology 2012-11, Vol.259 (11), p.2293-2298 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2298 |
|---|---|
| container_issue | 11 |
| container_start_page | 2293 |
| container_title | Journal of neurology |
| container_volume | 259 |
| creator | Outteryck, Olivier Ongagna, Jean-Claude Duhamel, Alain Zéphir, Hélène Collongues, Nicolas Lacour, Arnaud Fleury, Marie-Céline Berteloot, Anne-Sophie Blanc, Frédéric Giroux, Marianne Vermersch, Patrick de Sèze, Jérôme |
| description | To measure the prevalence of JCV-specific antibodies in a French cohort of MS patients treated with natalizumab and to identify risk factor(s) of JCV seropositivity. Progressive multifocal leukoencephalopathy (PML) risk may be stratified by anti-JCV antibody status, duration of natalizumab therapy (≥24 months) and prior exposure to immunosuppressive (IS) drugs. No data are available in France on the prevalence of anti-JCV antibodies and distribution of PML risk factors in patients treated with natalizumab. Sera of 361 patients under natalizumab therapy in two MS centers were analyzed using a previously validated ELISA test. We studied different characteristics: demographic, ethnic, radiological, clinical, prior use of immunomodulatory (IM) or IS drugs and natalizumab exposure duration. The JCV seropositivity rate was 51 % for the whole cohort. Mean natalizumab exposure duration was 27.27 months ± 15.57 (mean ± SD), and prior use of IS drugs was observed in 15.24 % of patients. Twenty-three patients (6.4 %) presented the three PML risk factors. By multivariate analysis, presence of anti-JCV antibodies was significantly linked to age, North African origin and natalizumab exposure duration. Anti-JCV antibody prevalence was similar to previously published data. Anti-JCV antibody status was linked to age. We also suggested that anti-JCV antibody status could be linked to natalizumab exposure duration and ethnic characteristics. |
| doi_str_mv | 10.1007/s00415-012-6487-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1171893857</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2802258591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-7140d7a9cb580bad678140ee70461c8b757672ba0898e21b675705487b2064493</originalsourceid><addsrcrecordid>eNp1kFFrFDEQgENR2mv1B_RFAiL4EjvJJpvsYzlaq1R8qIpvYZLN9bbsZddkVzh_vTnuWkXwKcPMN5OZj5BzDu84gL7IAJIrBlywWhrN1BFZcFkJxqVqnpEFVBKYqpQ8Iac5PwCAKYVjciKEEloIvSDfL-PUsY_LbxRL4IZ2S8cUfmIfog-0ixTpdSrxmvphPaSJDiv66Y6OOHUhTpnOsQ2JRpyw737NG3R0WoeE4_YFeb7CPoeXh_eMfL2--rK8Ybef339YXt4yLys1Mc0ltBob75QBh22tTcmEoEHW3Bunla61cAimMUFwV5cEqHKsE1BL2VRn5O1-7piGH3PIk9102Ye-xxiGOVvONTdNZZQu6Ot_0IdhTrFsVyghpABjoFB8T_k05JzCyo6p22DaWg52p93utdui3e60W1V6Xh0mz24T2qeOR88FeHMAMHvsVwmj7_Ifrq6FMtXuGrHncinF-5D-WvG_v_8GFuuXHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1122420880</pqid></control><display><type>article</type><title>Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Outteryck, Olivier ; Ongagna, Jean-Claude ; Duhamel, Alain ; Zéphir, Hélène ; Collongues, Nicolas ; Lacour, Arnaud ; Fleury, Marie-Céline ; Berteloot, Anne-Sophie ; Blanc, Frédéric ; Giroux, Marianne ; Vermersch, Patrick ; de Sèze, Jérôme</creator><creatorcontrib>Outteryck, Olivier ; Ongagna, Jean-Claude ; Duhamel, Alain ; Zéphir, Hélène ; Collongues, Nicolas ; Lacour, Arnaud ; Fleury, Marie-Céline ; Berteloot, Anne-Sophie ; Blanc, Frédéric ; Giroux, Marianne ; Vermersch, Patrick ; de Sèze, Jérôme</creatorcontrib><description>To measure the prevalence of JCV-specific antibodies in a French cohort of MS patients treated with natalizumab and to identify risk factor(s) of JCV seropositivity. Progressive multifocal leukoencephalopathy (PML) risk may be stratified by anti-JCV antibody status, duration of natalizumab therapy (≥24 months) and prior exposure to immunosuppressive (IS) drugs. No data are available in France on the prevalence of anti-JCV antibodies and distribution of PML risk factors in patients treated with natalizumab. Sera of 361 patients under natalizumab therapy in two MS centers were analyzed using a previously validated ELISA test. We studied different characteristics: demographic, ethnic, radiological, clinical, prior use of immunomodulatory (IM) or IS drugs and natalizumab exposure duration. The JCV seropositivity rate was 51 % for the whole cohort. Mean natalizumab exposure duration was 27.27 months ± 15.57 (mean ± SD), and prior use of IS drugs was observed in 15.24 % of patients. Twenty-three patients (6.4 %) presented the three PML risk factors. By multivariate analysis, presence of anti-JCV antibodies was significantly linked to age, North African origin and natalizumab exposure duration. Anti-JCV antibody prevalence was similar to previously published data. Anti-JCV antibody status was linked to age. We also suggested that anti-JCV antibody status could be linked to natalizumab exposure duration and ethnic characteristics.</description><identifier>ISSN: 0340-5354</identifier><identifier>EISSN: 1432-1459</identifier><identifier>DOI: 10.1007/s00415-012-6487-5</identifier><identifier>PMID: 22527227</identifier><identifier>CODEN: JNRYA9</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adolescent ; Adult ; Age ; Aged ; Antibodies ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Viral - biosynthesis ; Biological and medical sciences ; Chi-square test ; Cohort Studies ; Data processing ; Demography ; Drugs ; Enzyme-linked immunosorbent assay ; Female ; France - epidemiology ; Humans ; Immunomodulation ; Immunosuppressive agents ; JC Virus - immunology ; Leukoencephalopathy, Progressive Multifocal - epidemiology ; Leukoencephalopathy, Progressive Multifocal - immunology ; Leukoencephalopathy, Progressive Multifocal - virology ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - epidemiology ; Multiple Sclerosis - immunology ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Multivariate analysis ; Natalizumab ; Neurology ; Neuroradiology ; Neurosciences ; Original Communication ; Prevalence ; Progressive multifocal leukoencephalopathy ; Regression analysis ; Risk factors ; Statistical analysis ; Variables ; Young Adult</subject><ispartof>Journal of neurology, 2012-11, Vol.259 (11), p.2293-2298</ispartof><rights>Springer-Verlag 2012</rights><rights>2015 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-7140d7a9cb580bad678140ee70461c8b757672ba0898e21b675705487b2064493</citedby><cites>FETCH-LOGICAL-c435t-7140d7a9cb580bad678140ee70461c8b757672ba0898e21b675705487b2064493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00415-012-6487-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00415-012-6487-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26625839$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22527227$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Outteryck, Olivier</creatorcontrib><creatorcontrib>Ongagna, Jean-Claude</creatorcontrib><creatorcontrib>Duhamel, Alain</creatorcontrib><creatorcontrib>Zéphir, Hélène</creatorcontrib><creatorcontrib>Collongues, Nicolas</creatorcontrib><creatorcontrib>Lacour, Arnaud</creatorcontrib><creatorcontrib>Fleury, Marie-Céline</creatorcontrib><creatorcontrib>Berteloot, Anne-Sophie</creatorcontrib><creatorcontrib>Blanc, Frédéric</creatorcontrib><creatorcontrib>Giroux, Marianne</creatorcontrib><creatorcontrib>Vermersch, Patrick</creatorcontrib><creatorcontrib>de Sèze, Jérôme</creatorcontrib><title>Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy</title><title>Journal of neurology</title><addtitle>J Neurol</addtitle><addtitle>J Neurol</addtitle><description>To measure the prevalence of JCV-specific antibodies in a French cohort of MS patients treated with natalizumab and to identify risk factor(s) of JCV seropositivity. Progressive multifocal leukoencephalopathy (PML) risk may be stratified by anti-JCV antibody status, duration of natalizumab therapy (≥24 months) and prior exposure to immunosuppressive (IS) drugs. No data are available in France on the prevalence of anti-JCV antibodies and distribution of PML risk factors in patients treated with natalizumab. Sera of 361 patients under natalizumab therapy in two MS centers were analyzed using a previously validated ELISA test. We studied different characteristics: demographic, ethnic, radiological, clinical, prior use of immunomodulatory (IM) or IS drugs and natalizumab exposure duration. The JCV seropositivity rate was 51 % for the whole cohort. Mean natalizumab exposure duration was 27.27 months ± 15.57 (mean ± SD), and prior use of IS drugs was observed in 15.24 % of patients. Twenty-three patients (6.4 %) presented the three PML risk factors. By multivariate analysis, presence of anti-JCV antibodies was significantly linked to age, North African origin and natalizumab exposure duration. Anti-JCV antibody prevalence was similar to previously published data. Anti-JCV antibody status was linked to age. We also suggested that anti-JCV antibody status could be linked to natalizumab exposure duration and ethnic characteristics.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Antibodies</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Viral - biosynthesis</subject><subject>Biological and medical sciences</subject><subject>Chi-square test</subject><subject>Cohort Studies</subject><subject>Data processing</subject><subject>Demography</subject><subject>Drugs</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Female</subject><subject>France - epidemiology</subject><subject>Humans</subject><subject>Immunomodulation</subject><subject>Immunosuppressive agents</subject><subject>JC Virus - immunology</subject><subject>Leukoencephalopathy, Progressive Multifocal - epidemiology</subject><subject>Leukoencephalopathy, Progressive Multifocal - immunology</subject><subject>Leukoencephalopathy, Progressive Multifocal - virology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - epidemiology</subject><subject>Multiple Sclerosis - immunology</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Multivariate analysis</subject><subject>Natalizumab</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Original Communication</subject><subject>Prevalence</subject><subject>Progressive multifocal leukoencephalopathy</subject><subject>Regression analysis</subject><subject>Risk factors</subject><subject>Statistical analysis</subject><subject>Variables</subject><subject>Young Adult</subject><issn>0340-5354</issn><issn>1432-1459</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kFFrFDEQgENR2mv1B_RFAiL4EjvJJpvsYzlaq1R8qIpvYZLN9bbsZddkVzh_vTnuWkXwKcPMN5OZj5BzDu84gL7IAJIrBlywWhrN1BFZcFkJxqVqnpEFVBKYqpQ8Iac5PwCAKYVjciKEEloIvSDfL-PUsY_LbxRL4IZ2S8cUfmIfog-0ixTpdSrxmvphPaSJDiv66Y6OOHUhTpnOsQ2JRpyw737NG3R0WoeE4_YFeb7CPoeXh_eMfL2--rK8Ybef339YXt4yLys1Mc0ltBob75QBh22tTcmEoEHW3Bunla61cAimMUFwV5cEqHKsE1BL2VRn5O1-7piGH3PIk9102Ye-xxiGOVvONTdNZZQu6Ot_0IdhTrFsVyghpABjoFB8T_k05JzCyo6p22DaWg52p93utdui3e60W1V6Xh0mz24T2qeOR88FeHMAMHvsVwmj7_Ifrq6FMtXuGrHncinF-5D-WvG_v_8GFuuXHg</recordid><startdate>20121101</startdate><enddate>20121101</enddate><creator>Outteryck, Olivier</creator><creator>Ongagna, Jean-Claude</creator><creator>Duhamel, Alain</creator><creator>Zéphir, Hélène</creator><creator>Collongues, Nicolas</creator><creator>Lacour, Arnaud</creator><creator>Fleury, Marie-Céline</creator><creator>Berteloot, Anne-Sophie</creator><creator>Blanc, Frédéric</creator><creator>Giroux, Marianne</creator><creator>Vermersch, Patrick</creator><creator>de Sèze, Jérôme</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20121101</creationdate><title>Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy</title><author>Outteryck, Olivier ; Ongagna, Jean-Claude ; Duhamel, Alain ; Zéphir, Hélène ; Collongues, Nicolas ; Lacour, Arnaud ; Fleury, Marie-Céline ; Berteloot, Anne-Sophie ; Blanc, Frédéric ; Giroux, Marianne ; Vermersch, Patrick ; de Sèze, Jérôme</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-7140d7a9cb580bad678140ee70461c8b757672ba0898e21b675705487b2064493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Antibodies</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Viral - biosynthesis</topic><topic>Biological and medical sciences</topic><topic>Chi-square test</topic><topic>Cohort Studies</topic><topic>Data processing</topic><topic>Demography</topic><topic>Drugs</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Female</topic><topic>France - epidemiology</topic><topic>Humans</topic><topic>Immunomodulation</topic><topic>Immunosuppressive agents</topic><topic>JC Virus - immunology</topic><topic>Leukoencephalopathy, Progressive Multifocal - epidemiology</topic><topic>Leukoencephalopathy, Progressive Multifocal - immunology</topic><topic>Leukoencephalopathy, Progressive Multifocal - virology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - epidemiology</topic><topic>Multiple Sclerosis - immunology</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Multivariate analysis</topic><topic>Natalizumab</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Original Communication</topic><topic>Prevalence</topic><topic>Progressive multifocal leukoencephalopathy</topic><topic>Regression analysis</topic><topic>Risk factors</topic><topic>Statistical analysis</topic><topic>Variables</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Outteryck, Olivier</creatorcontrib><creatorcontrib>Ongagna, Jean-Claude</creatorcontrib><creatorcontrib>Duhamel, Alain</creatorcontrib><creatorcontrib>Zéphir, Hélène</creatorcontrib><creatorcontrib>Collongues, Nicolas</creatorcontrib><creatorcontrib>Lacour, Arnaud</creatorcontrib><creatorcontrib>Fleury, Marie-Céline</creatorcontrib><creatorcontrib>Berteloot, Anne-Sophie</creatorcontrib><creatorcontrib>Blanc, Frédéric</creatorcontrib><creatorcontrib>Giroux, Marianne</creatorcontrib><creatorcontrib>Vermersch, Patrick</creatorcontrib><creatorcontrib>de Sèze, Jérôme</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Outteryck, Olivier</au><au>Ongagna, Jean-Claude</au><au>Duhamel, Alain</au><au>Zéphir, Hélène</au><au>Collongues, Nicolas</au><au>Lacour, Arnaud</au><au>Fleury, Marie-Céline</au><au>Berteloot, Anne-Sophie</au><au>Blanc, Frédéric</au><au>Giroux, Marianne</au><au>Vermersch, Patrick</au><au>de Sèze, Jérôme</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy</atitle><jtitle>Journal of neurology</jtitle><stitle>J Neurol</stitle><addtitle>J Neurol</addtitle><date>2012-11-01</date><risdate>2012</risdate><volume>259</volume><issue>11</issue><spage>2293</spage><epage>2298</epage><pages>2293-2298</pages><issn>0340-5354</issn><eissn>1432-1459</eissn><coden>JNRYA9</coden><abstract>To measure the prevalence of JCV-specific antibodies in a French cohort of MS patients treated with natalizumab and to identify risk factor(s) of JCV seropositivity. Progressive multifocal leukoencephalopathy (PML) risk may be stratified by anti-JCV antibody status, duration of natalizumab therapy (≥24 months) and prior exposure to immunosuppressive (IS) drugs. No data are available in France on the prevalence of anti-JCV antibodies and distribution of PML risk factors in patients treated with natalizumab. Sera of 361 patients under natalizumab therapy in two MS centers were analyzed using a previously validated ELISA test. We studied different characteristics: demographic, ethnic, radiological, clinical, prior use of immunomodulatory (IM) or IS drugs and natalizumab exposure duration. The JCV seropositivity rate was 51 % for the whole cohort. Mean natalizumab exposure duration was 27.27 months ± 15.57 (mean ± SD), and prior use of IS drugs was observed in 15.24 % of patients. Twenty-three patients (6.4 %) presented the three PML risk factors. By multivariate analysis, presence of anti-JCV antibodies was significantly linked to age, North African origin and natalizumab exposure duration. Anti-JCV antibody prevalence was similar to previously published data. Anti-JCV antibody status was linked to age. We also suggested that anti-JCV antibody status could be linked to natalizumab exposure duration and ethnic characteristics.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>22527227</pmid><doi>10.1007/s00415-012-6487-5</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-5354 |
| ispartof | Journal of neurology, 2012-11, Vol.259 (11), p.2293-2298 |
| issn | 0340-5354 1432-1459 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1171893857 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Adult Age Aged Antibodies Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Viral - biosynthesis Biological and medical sciences Chi-square test Cohort Studies Data processing Demography Drugs Enzyme-linked immunosorbent assay Female France - epidemiology Humans Immunomodulation Immunosuppressive agents JC Virus - immunology Leukoencephalopathy, Progressive Multifocal - epidemiology Leukoencephalopathy, Progressive Multifocal - immunology Leukoencephalopathy, Progressive Multifocal - virology Male Medical sciences Medicine Medicine & Public Health Middle Aged Multiple Sclerosis - drug therapy Multiple Sclerosis - epidemiology Multiple Sclerosis - immunology Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Multivariate analysis Natalizumab Neurology Neuroradiology Neurosciences Original Communication Prevalence Progressive multifocal leukoencephalopathy Regression analysis Risk factors Statistical analysis Variables Young Adult |
| title | Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T12%3A47%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-JCV%20antibody%20prevalence%20in%20a%20French%20cohort%20of%20MS%20patients%20under%20natalizumab%20therapy&rft.jtitle=Journal%20of%20neurology&rft.au=Outteryck,%20Olivier&rft.date=2012-11-01&rft.volume=259&rft.issue=11&rft.spage=2293&rft.epage=2298&rft.pages=2293-2298&rft.issn=0340-5354&rft.eissn=1432-1459&rft.coden=JNRYA9&rft_id=info:doi/10.1007/s00415-012-6487-5&rft_dat=%3Cproquest_cross%3E2802258591%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1122420880&rft_id=info:pmid/22527227&rfr_iscdi=true |